Skip to main content

Vistin Pharma ASA: First quarter 2021 financial results

Written by Customer Service on . Posted in Public Companies.

Oslo, Norway, 23rd of April 2021

Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial results for the first quarter 2021

Vistin Pharma delivers another strong quarter with 15% increase in revenue YoY. Q1’21 revenue ended at MNOK 70.8 (Q1’20: MNOK 61.4).

First quarter EBITDA for pharmaceuticals was MNOK 16.3 (Q1’20: MNOK 14.2) a 15% increase compared to similar quarter last year

The net profit for the group ended at MNOK 8.8 (Q1’20: negative MNOK 168) for the first quarter of 2021. The net loss in Q1’20 was driven by closing of the oil derivative contracts.

Vistin Pharma had cash of MNOK 85 (Q1’20 MNOK: 317) as of 31 March 2021. Approx. 35% of the Metformin Expansion Project (MEP) has been paid as of March. The company has a strong balance sheet with an equity ratio of 86% and no interest-bearing debt.  

The Fikkjebakke plant has been running at full capacity an achieved an all-time high production volume in the quarter driven by full effect of the 2nd reactor installed in Q3/Q4’20

The first quarter conference call, which will be held today, 23rd of April, at 8.30am (CET) and will be available via web and audio through the following access points:

Telephone conference:
Confirmation Code:…….. 4598958
International Dial-In:……. +44 (0) 2071 928338
Norway, Oslo:……………. +47 21563015
United States, New York: +1 6467413167

Webcast:
https://edge.media-server.com/mmc/p/rso5ngk4

The conference call will be held in Norwegian.
       

Please find the Q1 report and presentation enclosed. The report will also be made available on www.vistin.com.

*****

For further information, please contact:

Kjell-Erik Nordby
CEO
+47 91 36 42 80
kjell-erik.nordby@vistin.com

Alexander Karlsen
CFO
+47 97 05 36 21
alexander.karlsen@vistin.com

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Attachments

  • Vistin Pharma ASA first quarter report 2021
  • Vistin Pharma ASA first quarter presentation 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.